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ABSTRACT
Introduction: This sub-analysis evaluated
clinical safety and effectiveness of bolus
insulin aspart [with/without oral glucose-
lowering drugs (OGLDs)] as the only insulin
therapy.
Methods: A1chieve was an international,
multicenter, prospective, open-label, non-
interventional, observational, 24-week study in
people with type 2 diabetes mellitus starting/
switching to biphasic insulin aspart 30, insulin
detemir or insulin aspart treatment (alone/in
combination) in routine clinical practice. This
sub-analysis evaluated clinical safety and
effectiveness of bolus insulin aspart (±OGLDs)
as the only insulin therapy. Data were analyzed
for all patients, insulin-experienced and insulin-
naive sub-groups, and sub-groups defined by
the number of OGLDs prescribed at baseline (no
OGLDs, one OGLD or Ctwo OGLDs). Safety
and effectiveness endpoints were assessed at
baseline and following 24 weeks’ therapy.
The A1chieve trial was registered with ClinicalTrials.gov
(NCT00869908).
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Results: In total, 2,026 patients were included
(insulin-experienced, n = 561; insulin-naive,
n = 1,465) in this sub-analysis. Significant
improvements from baseline after 24 weeks’
treatment with insulin aspart ± OGLDs were
observed across all sub-groups for: glycated
hemoglobin (range of means across sub-groups
-1.6 to -2.4%; p\0.001 for all comparisons),
fasting plasma glucose (-2.5 to -3.8 mmol/l;
p\0.001 for all comparisons), post-breakfast
post-prandial glucose (-3.4 to -5.8 mmol/l;
p\0.001 for all comparisons), and health-
related quality of life (HRQoL; p\0.001 for all
comparisons). The proportion of patients
reporting hypoglycemia events was
significantly reduced from baseline after
24 weeks (insulin-naive cohort: 7.9–2.8%;
p\0.001; insulin-experienced cohort:
23.2–7.8%; p\0.001). There were no reports
of major hypoglycemia events at 24 weeks; risk
of nocturnal hypoglycemia was \0.6 events/
person-year. No serious adverse drug reactions
were reported.
Conclusion: Insulin aspart ± OGLDs is
associated with significant improvements in
glycemic control and HRQoL, without
increased risk of hypoglycemia, in people with
type 2 diabetes and sub-optimal glucose
control.
Keywords: A1chieve study; Bolus only; Insulin
aspart; Oral glucose-lowering drugs; Type 2
diabetes
INTRODUCTION
Increased life expectancy and high global
prevalence of type 2 diabetes mellitus [1, 2]
render treatment of this condition a lifelong
personal and social burden [3–5]. Post-prandial
hyperglycemia is a common phenomenon in
people with type 1 and 2 diabetes, and incurs a
significant risk of diabetes-related
complications [6]. Therefore, achieving control
of post-prandial glucose (PPG) level and fasting
plasma glucose (FPG) level is important to
maintain glycated hemoglobin (HbA1c) levels
below target [6]. Despite the need to control
PPG, the number of available drugs able to
accomplish this is limited. Conventional oral
glucose-lowering drugs (OGLDs) and lifestyle
modifications, while fundamental to early
management of the disease, are unable to
maintain good glycemic control in the longer
term, and there is a consequent additional
requirement for exogenous insulin [7, 8].
Compared with exogenous human insulin,
the rapid-acting analog insulin aspart
(NovoRapid; Novo Nordisk A/S, Bagsvaerd,
Denmark) is associated with rapid absorption
and early onset of action, which facilitates
administration immediately before or shortly
after a meal [9]. Subcutaneous administration of
rapid-acting insulin analogs results in a
physiologic profile that bears a closer
resemblance to endogenous insulin than is
achieved with subcutaneous administration of
human insulin. By virtue of this action, insulin
analogs, such as insulin aspart, offer advantages
over human insulin (e.g., greater convenience
[10]) and have the potential to reduce PPG
excursions, thereby improving overall glycemic
control [11, 12]. Clinical research shows that
insulin aspart is also associated with reduced
hypoglycemia risk and greater treatment
satisfaction versus human insulin when
administered in a basal-bolus regimen among
people with type 1 and 2 diabetes mellitus [13–
18]. Guidelines generally recommend initiating
insulin therapy when OGLDs fail to provide
adequate glycemic control [19]; in this context,
some healthcare professionals start patients on
prandial insulin as the only insulin therapy [20,
21]. While few studies have examined the safety
154 Diabetes Ther (2013) 4:153–166
123
and effectiveness of bolus-only insulin aspart,
particularly as add-on to OGLDs, available
evidence suggests beneficial effects on
glycemic control when OGLD therapy is
insufficient [22].
While well-designed randomized controlled
trials provide a stringent way of assessing
insulin regimens, they focus on a selected
patient group under intensive clinical
supervision. Therefore, results obtained from
such studies may not be truly representative of
routine clinical practice. In addition,
randomized controlled trials are often
performed in restricted geographical regions,
with less focus on those countries that are less
well resourced. While observational studies are
associated with limitations, such as lack of a
control group, they are capable of enrolling a
larger cohort of people from diverse geographic
locations and environments, and may better
represent everyday clinical practice than
randomized controlled trials.
A1chieve was an international observational
study evaluating the safety and effectiveness of
insulin analogs in people with type 2 diabetes
mellitus receiving routine clinical care in 28
countries across four continents [20]. This sub-
group analysis of participants from the A1chieve
study aimed to investigate the clinical safety
and effectiveness of insulin aspart alone or as
add-on to OGLDs for the management of type 2
diabetes mellitus in routine clinical practice.
MATERIALS AND METHODS
Study Design
A1chieve was a 24-week, international,
prospective, multicenter, non-interventional,
observational study examining the safety and
effectiveness of insulin analogs in 66,276 people
with type 2 diabetes mellitus undergoing
treatment in routine clinical practice between
January 2009 and June 2010 [20]. The study was
conducted across 3,166 centers in 28 countries,
representing seven geographical regions: China,
South Asia (Bangladesh, India, Pakistan), East
Asia (Indonesia, Korea, Malaysia, Philippines,
Singapore, Taiwan), North Africa (Algeria,
Morocco, Tunisia, Libya), Middle East (Egypt,
Iran, Jordan, Turkey, Bahrain, Kuwait, Oman,
Qatar, Saudi Arabia, UAE, Yemen), Latin
America (Argentina, Mexico), and Russia.
Insulin analogs (manufactured by Novo
Nordisk A/S, Bagsvaerd, Denmark) were used
in accordance with the label approved by the
regulatory authority, and all local requirements
for Health Authorities or Ethics Committee
approvals were obtained, if applicable.
Physicians were able to adjust treatment
during the 24 weeks. Details on inclusion and
exclusion criteria, and study design have been
reported elsewhere [20]. In every country,
participants gave informed consent and were
free to withdraw from the study at any time.
The study was conducted in accordance with
the Declaration of Helsinki of 1964, as revised in
2008 [23], and Guidelines for Good
Pharmacoepidemiology Practice [24].
Results presented here are from a sub-
analysis of patients treated with insulin aspart
alone or in combination with OGLDs
(excluding those who received basal-bolus
insulin regimens).
Assessments
Assessments were at baseline (time when the
treating physician prescribed insulin aspart),
approximately 12 weeks after baseline (results
not reported here), and study end
(approximately 24 weeks after baseline).
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The primary objective of the study was to
evaluate the safety profile of insulin analogs
by measuring the incidence of serious adverse
drug reactions (SADRs), including major
hypoglycemia events. Other safety assessments
included change in the number of
hypoglycemia events between baseline and
24 weeks (reported as the percentage of
patients reporting an event and events/person
year). These were based on patient recall of
events within the preceding 4 weeks of the
study visit.
Effectiveness of therapy was determined
from measurements made by the treating
physician team at each assessment visit; data
were collated into a standard case report form
using information from the physicians’
clinical notes and the participants’ recall and
self-monitoring diary/meter. Effectiveness
outcomes included change from baseline
after 24 weeks in glucose control measures
[HbA1c; FPG (pre-breakfast), and PPG
(90–120 min after beginning breakfast)], body
weight, and health-related quality of life
(HRQoL). HRQoL was measured at baseline
and after 24 weeks by self-report using the EQ-
5D questionnaire [25], which evaluates five
domains of patient health/lifestyle (mobility,
self-care, usual activities, pain/discomfort, and
anxiety/depression). The questionnaire also
includes a rating for an individual’s current
HRQoL on a visual analog scale [VAS; ranging
from 0 (worst imaginable health) to 100 (best
imaginable health)]. Scores in the five
domains were converted to a single utility
value (UK VAS set), with ‘1.00’ indicating ‘full
health’ and ‘0.00’ indicating ‘deceased’ [26,
27].
Due to the non-interventional design of the
analysis and lack of protocol enforcement to
report all outcomes, data are described here as
per available reports.
Statistical Analyses
Analyses were performed on data from all
patients with a baseline visit who were treated
with insulin aspart at least once during the
study. For those patients who withdrew from the
study, data collected until the date of
withdrawal were used for analysis. Patients
were split into two cohorts according to
whether they had received insulin before the
study (insulin-experienced and insulin-naive) or
not. Sub-group analyses were then conducted in
each cohort according to the number of OGLDs
received at baseline (none, one, or Ctwo).
Changes from baseline in effectiveness
measures were assessed using Student’s paired
t test. For hypoglycemia, the percentage of
patients reporting at least one event was
analyzed using McNemar’s test. All statistical
analyses were two-sided, using a pre-specified
5% significance level, and were performed by
Novo Nordisk A/S using SAS Version 9.1.3
(SAS Institute Inc., Cary, NC, USA).
RESULTS
Study Participants
In total, 3,898 patients from the A1chieve study
received treatment with insulin aspart alone or
in combination with OGLDs at baseline (insulin
aspart alone, n = 1,560; insulin aspart ? one
OGLD, n = 1,514; and insulin aspart ? Ctwo
OGLDs, n = 824) [20]. Of these, 1,872 patients
subsequently switched to insulin analog basal-
bolus regimens, basal insulin analog regimens,
or biphasic insulin analog regimens before
completing the study. Thus, 2026 people who
received insulin aspart alone or in combination
with OGLDs at baseline and after 24 weeks (or
last follow-up visit) were included in this
analysis (Table 1).
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Among treating physicians, the need to
improve glycemic control (93.0%) represented
the predominant reason for changing/switching
to insulin aspart therapy followed by the need
to reduce the risk of hypoglycemia (44.9%) and
reduce variability of plasma glucose levels
(27.8%). Among insulin-experienced patients
(n = 561), previous insulin therapies included
premix human insulin (42.1% of patients),
human soluble insulin (20.7%), insulin
glargine (15.9%), neutral protamine Hagedorn
(NPH, 7.0%), NPH plus human soluble insulin
(3.6%), and others such as premixed insulin
lispro (10.9%). Baseline characteristics were
generally similar between patient sub-groups,
although insulin-experienced patients appeared
to have had longer mean diabetes duration and
longer time since OGLD initiation than insulin-
naive patients (Table 1). In both insulin-
experienced and insulin-naive patients,
metformin was the most frequently prescribed
OGLD pre-study (71% and 80% of patients,
respectively), and sulfonylurea was the second
most frequently prescribed (44% and 64% of
patients, respectively).
Insulin Dose
Insulin-experienced patients received a mean
(standard deviation; SD) insulin dose of 0.50




















n (% of cohort) 561 (100) 270 (48.1) 187 (33.3) 104 (18.5) 1,465 (100) 514 (35.1) 568 (38.8) 383 (26.1)
Mean (SD) age
(years)a
55.8 (13.4) 55.2 (14.6) 55.9 (12.6) 57.6 (11.1) 51.5 (13.3) 53.3 (15.4) 51.0 (12.3) 49.8 (11.2)
Male gender (%) 56.9 59.3 54.5 54.8 59.0 57.0 60.6 59.3
Mean (SD) body
weight (kg)b
68.7 (14.6) 67.2 (15.2) 69.6 (14.9) 71.1 (11.7) 67.3 (12.9) 65.7 (13.6) 67.3 (12.6) 69.4 (12.3)
Mean (SD) BMI
(kg/m2)c












8.3 (6.4) 6.7 (6.0) 9.8 (7.1) 9.5 (5.4) 4.8 (4.6) 3.9 (4.9) 5.3 (4.5) 5.3 (4.1)
Due to the observational nature of the study not all measures were reported/collected
BMI body mass index, OGLDs oral glucose-lowering drugs
a In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 548, n = 267, n = 184 and n = 97, respectively; insulin-naive,
n = 1,418, n = 506, n = 540 and n = 372, respectively
b In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 526, n = 258, n = 182 and n = 86, respectively; insulin-naive,
n = 1,388, n = 477, n = 538 and n = 373, respectively
c In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 489, n = 246, n = 167 and n = 76, respectively; insulin-naive,
n = 1,312, n = 452, n = 506 and n = 354, respectively
d In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 556, n = 267, n = 185 and n = 104, respectively; insulin-naive,
n = 1,447, n = 505, n = 561 and n = 381, respectively
e In the total, no OGLD, one OGLD and Ctwo OGLD groups n = 500, n = 242, n = 160 and n = 98, respectively
f In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 530, n = 254, n = 174 and n = 102, respectively; insulin-naive,
n = 1,341, n = 467, n = 520 and n = 354, respectively
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(0.29) U (or IU)/kg before entering the study.
When patients switched to insulin
aspart ± OGLDs at baseline the dose ranged
from 0.45 to 0.47 U/kg in the different sub-
groups (Fig. 1). In the insulin-naive cohort,
mean (SD) insulin aspart dose was 0.40
(0.20) U/kg at baseline (Fig. 1). Following
24 weeks’ therapy with insulin aspart, there
were no obvious changes from baseline in
mean insulin dose in either cohort (Fig. 1).
The proportion of insulin-experienced
patients receiving once daily (qd), twice daily
(bid), or Cthree times daily (tid) insulin aspart
injections at baseline was 7.1%, 27.3%, and
65.5%, respectively. Insulin injection frequency
was similar to baseline following 24 weeks of
therapy with insulin aspart (7.8%, 32.5%, and
59.7% of patients, respectively). The proportion
of insulin-naive patients receiving qd, bid, or
Ctid insulin injections at baseline was 5.5%,
40.2%, and 54.3%, respectively. Insulin
injection frequency was similar to baseline
following 24 weeks of insulin aspart therapy
(5.4%, 44.9%, and 49.6% of patients,
respectively).
Number of OGLDs
Most insulin-experienced and insulin-naive
patients were receiving the same number of
OGLDs at baseline and following 24 weeks of
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Fig. 1 Mean (SD) insulin dose received by patients at
baseline and after 24 weeks on insulin aspart therapy in the
A1chieve study. Due to the observational nature of the
study not all measures were reported/collected. At baseline:
insulin-experienced: n = 257 in 0 OGLD sub-group;
n = 182 in 1 OGLD sub-group; n = 86 in C2 OGLDs
sub-group. Insulin-naive: n = 477 in 0 OGLD sub-group;
n = 536 in 1 OGLD sub-group; n = 373 in C2 OGLDs
sub-group. After 24 weeks: insulin-experienced: n = 178 in
0 OGLD sub-group; n = 138 in 1 OGLD sub-group;
n = 64 in C2 OGLDs sub-group. Insulin-naive: n = 326
in 0 OGLD sub-group; n = 422 in 1 OGLD sub-group;
n = 274 in C2 OGLDs sub-group. OGLD oral glucose-
lowering drug
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insulin-experienced (209/367, 56.9%) and
insulin-naive (408/795, 51.3%) patients
receiving insulin aspart injections Ctid at
baseline were not taking OGLDs. However,
most insulin-experienced (22/40, 55.0%) and
insulin-naive (43/82, 52.4%) patients taking qd
insulin aspart injections at baseline were
receiving Ctwo OGLDs at baseline. In insulin-
experienced patients receiving bid insulin aspart
injections at baseline, the proportion of patients
taking no OGLDs, one OGLD, or Ctwo OGLDs at
baseline was similar (52/154, 33.8%; 60/154,
39.0%; and 42/154, 27.3%, respectively). Most
insulin-naive patients receiving bid insulin
aspart injections were receiving one OGLD or
Ctwo OGLDs at baseline (270/588, 45.9% and
221/588, 37.6%, respectively).
Metformin and/or sulfonylureas were the
predominant OGLDs administered in all sub-
groups of patients; [60% of patients in all sub-
groups were receiving metformin after 24 weeks.
Serious Adverse Events
Following 24 weeks of insulin aspart therapy,
six serious adverse events (SAEs) were reported,
which were considered unlikely to be related to
the study treatment. In the insulin-naive
cohort, three SAEs (one incident of acute
cardiac failure, one malignant lung neoplasm,
and one case of chronic renal failure) were
reported in the group receiving no OGLDs at
baseline and one SAE (vascular stenosis) was
reported in the group receiving one OGLD at
baseline; two deaths (one acute cardiac failure
and the other malignant lung neoplasm) were
reported in the insulin-naive cohort. In the
insulin-experienced cohort, two SAEs were
reported in the group receiving no OGLDs at
baseline: upper gastrointestinal hemorrhage
and hepatic coma. No other SAEs were reported.
Hypoglycemia Events
The proportion of insulin-experienced and
insulin-naive patients reporting at least one
hypoglycemia event was significantly decreased
from baseline following 24 weeks of treatment
with insulin aspart in patients receiving bid or
tid insulin injections (Table 3). The proportion
of patients reporting at least one hypoglycemia
event did not significantly change between
baseline and 24 weeks in patients receiving qd
or four times daily (qid) insulin injections

















All, n 191 151 83 376 457 298
No OGLDs, n
(% of cohort)
157 (82.2) 24 (15.9) 1 (1.2) 291 (77.4) 49 (10.7) 22 (7.4)
One OGLD, n
(% of cohort)
27 (14.1) 111 (73.5) 15 (18.1) 68 (18.1) 286 (62.6) 55 (18.5)
CTwo OGLDs,
n (% of cohort)
7 (3.7) 16 (10.6) 67 (80.7) 17 (4.5) 122 (26.7) 221 (74.2)
Due to the observational nature of the study not all measures were reported/collected
OGLDs oral glucose-lowering drugs
Diabetes Ther (2013) 4:153–166 159
123
(Table 3). There was no obvious effect of insulin
injection frequency on the proportion of
patients experiencing nocturnal hypoglycemia
events at 24 weeks in insulin-experienced and
insulin-naive patients (Table 3).
The proportion of patients reporting at least
one hypoglycemia event was significantly
decreased from baseline following 24 weeks of
treatment with insulin aspart, irrespective of
prior insulin experience and the number of
OGLDs received at baseline (Table 4); the
exception was no significant change between
baseline and 24 weeks in insulin-naive patients
who were receiving no OGLDs at baseline. The
proportion of patients reporting at least one
nocturnal hypoglycemia event was significantly
decreased from baseline to 24 weeks irrespective
of prior insulin experience and the number of
OGLDs received at baseline; the exceptions were
no change between baseline and 24 weeks in
insulin-experienced patients taking Ctwo
OGLDs at baseline, and insulin-naive patients
taking no OGLDs at baseline (Table 4).
At 24 weeks, no major hypoglycemia events
were reported in the insulin-experienced or
insulin-naive cohorts and the risk of nocturnal
hypoglycemia was reduced to \0.6 events/
person-year, irrespective of baseline insulin
Table 3 Safety outcomes before and after 24 weeks of treatment with insulin aspart alone or with OGLDs according to
baseline insulin injection frequency



















Baseline 10.0 (2.3) 16.2 (4.5) 28.1 (10.8) 22.5 (19.2) 2.4 (0.5) 12.8 (3.3) 5.1 (1.7) 2.3 (0.3)
n 40 154 327 40 82 588 751 44
24 weeks 0 (0) 7.8 (1.3)* 8.1 (1.9)*** 14.3 (2.3) 1.5 (0.6) 2.1 (0.5)*** 3.5 (1.2)* 4.0 (0.5)
n 33 128 236 28 66 466 574 25
Hypoglycemia (major)a
Baseline 2.5 (0.3) 5.2 (1.0) 5.8 (1.7) 7.5 (1.0) 0 (0) 1.7 (0.2) 0.7 (0.1) 0 (0)
24 weeks 0 (0)b 0 (0)** 0 (0)*** 0 (0) 0 (0)c 0 (0) 0 (0)* 0 (0)c
Hypoglycemia (nocturnal)a
Baseline 2.5 (0.3) 7.1 (1.4) 14.7 (3.0) 15.0 (8.5) 0 (0) 8.3 (1.3) 1.3 (0.3) 0 (0)
24 weeks 0 (0) 2.3 (0.3) 0 (0)*** 3.6 (0.5) 1.5 (0.2) 0.6 (0.1)*** 0.3 (0.1) 0 (0)c
Due to the observational nature of the study not all measures were reported/collected
*** p\0.001 vs. baseline
** p\0.01 vs. baseline
* p\0.05 vs. baseline
a n for each cohort same as for hypoglycemia (overall) data
b Statistical analysis could not be performed with McNemar’s test as patients reporting hypoglycemia at baseline were
missing hypoglycemia data for 24 weeks
c No hypoglycemia events were reported at baseline and 24 weeks; therefore statistical analysis could not be conducted
160 Diabetes Ther (2013) 4:153–166
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injection frequency and number of OGLDs
received. No other adverse reactions or serious
adverse reactions were reported that were
considered possibly related to the study
treatment.
Glucose Control
There were statistically significant
improvements in measures of blood glucose
control (PPG, FPG and HbA1c) after 24 weeks of
treatment with insulin aspart regardless of
concomitant OGLD use (p\0.001 versus
baseline for all measures across all sub-groups
in both the insulin-naive and insulin-
experienced cohorts; Table 5). There were no
obvious differences in these parameters
between sub-groups (Table 5).
Body Weight
Body weight remained stable throughout the
study for insulin-experienced patients,
irrespective of the number of OGLDs received
(Table 5). In the insulin-naive cohort, there was
a significant mean weight gain (0.6 kg) from
baseline at 24 weeks in patients receiving no
OGLDs at baseline and a significant weight loss
(-0.2 kg) in the sub-group receiving Ctwo
OGLDs at baseline (Table 5).
Table 4 Safety outcomes before and after 24 weeks of treatment with insulin aspart alone or with OGLDs according to
OGLDs taken at baseline





















Baseline 23.2 (9.1) 26.3 (11.4) 20.3 (6.8) 20.2 (7.1) 7.9 (2.2) 4.9 (1.8) 7.7 (1.8) 12.3 (3.5)
n 561 270 187 104 1,465 514 568 383
24 weeks 7.8 (1.6)*** 9.4 (2.2)*** 6.6 (1.4)*** 6.0 (0.8)* 2.8 (0.9)*** 4.3 (1.4) 2.6 (0.8)*** 1.3 (0.4)***
n 425 191 151 83 1,131 376 457 298
Hypoglycemia (major)a
Baseline 5.5 (1.3) 6.3 (1.8) 3.2 (0.6) 7.7 (1.4) 1.0 (0.2) 0.4 (0.1) 0.7 (0.1) 2.3 (0.3)
24 weeks 0 (0)*** 0 (0)*** 0 (0)* 0 (0)* 0 (0)** 0 (0) 0 (0)* 0 (0)
Hypoglycemia (nocturnal)a
Baseline 11.8 (2.8) 14.4 (3.2) 10.2 (2.4) 7.7 (2.1) 4.0 (0.7) 1.0 (0.3) 4.9 (0.6) 6.8 (1.2)
24 weeks 0.9 (0.1)*** 0.5 (0.1)*** 1.3 (0.2)** 1.2 (0.2) 0.5 (0.1)*** 1.1 (0.2) 0.4 (0.1)*** 0 (0)***
Due to the observational nature of the study not all measures were reported/collected
OGLDs oral glucose-lowering drugs
*** p\0.001 vs. baseline
** p\0.01 vs. baseline
* p\0.05 vs. baseline
a n for each cohort same as for hypoglycemia (overall) data
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Mean (SD) HbA1c (%)
Baseline 9.1 (2.1) 9.0 (2.2) 9.3 (2.1) 9.1 (1.6) 9.5 (1.9) 9.4 (2.2) 9.7 (1.9) 9.3 (1.5)
24 weeks 7.4 (1.1) 7.4 (1.2) 7.5 (1.1) 7.5 (1.0) 7.2 (1.1) 7.2 (1.1) 7.2 (1.1) 7.3 (1.1)
Change after
24 weeks
-1.7 (1.9)*** -1.6 (2.1)*** -1.9 (1.9)*** -1.7 (1.6)*** -2.2 (2.0)*** -2.1 (2.2)*** -2.4 (2.0)*** -2.1 (1.8)***
n 279 123 101 55 794 226 309 259
Mean (SD) HbA1c (mmol/mol)
Baseline 76 (23) 75 (24) 78 (23) 76 (17) 80 (21) 79 (24) 83 (21) 78 (16)
24 weeks 57 (12) 57 (13) 58 (12) 58 (11) 55 (12) 55 (12) 55 (12) 56 (12)
Change after
24 weeks
-19 (21)*** -17 (23)*** -21 (21)*** -19 (17)*** -24 (22)*** -23 (24)*** -26 (22)*** -23 (20)***
n 279 123 101 55 794 226 309 259
Mean (SD) FPG (mmol/l)
Baseline 9.9 (3.7) 9.6 (3.9) 10.1 (3.4) 10.0 (3.7) 10.8 (3.5) 10.2 (3.6) 11.7 (3.5) 10.3 (2.9)
24 weeks 7.1 (2.0) 7.1 (2.1) 7.0 (1.9) 7.3 (2.3) 7.4 (2.0) 7.1 (1.7) 7.9 (2.3) 7.0 (1.6)
Change after
24 weeks
-2.8 (3.6)*** -2.5 (3.9)*** -3.1 (3.2)*** -2.7 (3.3)*** -3.4 (3.0)*** -3.1 (3.3)*** -3.8 (3.0)*** -3.2 (2.7)***
n 329 155 119 55 990 303 412 275
Mean (SD) PPG (mmol/l)
Baseline 13.4 (4.5) 13.1 (4.8) 13.6 (4.1) 14.2 (4.3) 15.8 (4.7) 14.9 (5.2) 16.5 (4.4) 16.0 (4.1)
24 weeks 9.9 (2.9) 9.7 (2.7) 10.0 (3.0) 10.4 (3.3) 10.1 (3.2) 9.2 (2.9) 10.7 (3.4) 10.3 (2.8)
Change after
24 weeks
-3.5 (4.2)*** -3.4 (4.2)*** -3.6 (3.8)*** -3.8 (5.1)*** -5.8 (4.5) -5.7 (5.0)*** -5.8 (4.3)*** -5.7 (4.1)***
n 262 119 105 38 735 255 316 164
Mean (SD) body weight (kg)
Baseline 68.6 (13.8) 67.4 (13.7) 68.9 (14.7) 71.3 (11.9) 66.9 (12.4) 65.1 (12.8) 66.9 (11.6) 69.1 (12.7)
24 weeks 68.6 (13.1) 67.6 (12.9) 68.9 (14.2) 70.8 (10.7) 67.1 (11.8) 65.7 (12.0) 67.0 (11.1) 68.9 (12.4)
Change after
24 weeks
0.0 (2.6) 0.2 (2.6) 0.0 (2.5) -0.5 (2.4) 0.2 (2.8) 0.6 (3.7)** 0.1 (2.4) -0.2 (1.8)*
n 377 176 137 64 999 313 413 273
Mean (SD) HRQoL (UK VAS)
Baseline 0.672 (0.278) 0.706 (0.287) 0.694 (0.253) 0.567 (0.277) 0.621 (0.304) 0.768 (0.258) 0.577 (0.314) 0.513 (0.271)



















n 331 145 116 70 926 293 399 234
Due to the observational nature of the study not all measures were reported/collected
FPG fasting plasma glucose, pre-breakfast measurement, HbA1c glycated hemoglobin, HRQoL health-related quality of life, OGLDs oral glucose-lowering
drugs, PPG post-prandial plasma glucose, 90–120 min after the beginning of breakfast, VAS visual analog scale
*** p\0.001 vs. baseline
** p\ 0.01 vs. baseline
* p\0.05 vs. baseline
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Health-Related Quality of Life
Following 24 weeks of insulin aspart therapy,
statistically significant improvements from
baseline in UK VAS scores were observed in all
sub-groups of insulin-experienced and insulin-
naive patients (p\0.001 versus baseline for all
measures across all sub-groups in both the
insulin-naive and insulin-experienced cohorts;
Table 5).
DISCUSSION
In this sub-analysis of the A1chieve study,
patients who switched to/initiated therapy
with insulin aspart ± OGLDs, as part of routine
clinical practice, experienced statistically
significant improvements in HbA1c, FPG, and
PPG following 24 weeks of treatment. This was
achieved irrespective of previous insulin
experience and the number of concomitant
OGLDs received. Whereas the reduction in
PPG is expected with the use of insulin aspart,
the reduction in FPG level is not necessarily
anticipated with the use of prandial insulin
only. However, although few studies have
examined the effectiveness of bolus-only
insulin aspart, particularly as add-on to
OGLDs, available data are in line with current
findings [22, 28, 29]. In the INSTIGATE (INSulin
TItration—GAining an understanding of the
burden of Type 2 diabetes in Europe)
observational study, for example, reductions in
FPG were observed following 24 months of
prandial insulin therapy ± OGLDs, and
reductions in HbA1c (-2.2%) were similar to
those reported here [29].
Overall, 52% of the patients who switched
to/initiated therapy with insulin aspart alone or
in combination with OGLDs continued on this
insulin regimen for the duration of the study. In
the INSTIGATE study, 31% of the total cohort
who were receiving prandial insulin at baseline
continued to be managed on this regimen after
2 years of treatment [29]. These data suggest
that a prandial insulin regimen is able to
effectively control glucose levels over an
extended time in many patients.
While weight increases have been reported
with the longer-term use of prandial insulin
[22], weight remained stable from baseline to
24 weeks in this study, irrespective of prior
insulin experience and concomitant OGLD
use. There was a significant, but numerically
small, weight gain (0.6 kg) in a single sub-group;
the insulin-naive cohort receiving no OGLDs at
baseline.
Importantly, significant improvements in
glycemic control with insulin aspart were also
achieved without increasing the risk of
hypoglycemia events irrespective of insulin
injection frequency and OGLD use. There were
significant reductions in the proportion of
patients receiving bid or tid insulin aspart
injections who reported hypoglycemia events
regardless of prior insulin experience. This is
pertinent given the greater risk of hypoglycemia
events that might be expected with increasing
injection frequency. While there were
numerical reductions in the proportions of
insulin-experienced patients experiencing
hypoglycemia events in the groups receiving
qd or qid insulin injections, these might have
failed to reach statistical significance due to low
patient numbers. The proportion of patients
reporting hypoglycemia events in the insulin-
naive group not receiving OGLDs at baseline
did not significantly change between baseline
and 24 weeks. Improvements in hypoglycemia
were also achieved despite a high proportion of
patients in the insulin-experienced and insulin-
naive cohorts receiving sulfonylureas at
24 weeks (35.4% and 41.4% of patients,
respectively). There were no reports of major
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hypoglycemia events in the 4 weeks preceding
the assessment at 24 weeks, and nocturnal
hypoglycemia was reduced to low rates (\0.6
events/person-year) in all sub-groups of
patients, as would be expected from the
clinical profile of insulin aspart [10]. While
guidelines recommend discontinuation of
sulfonylureas on commencement of prandial
insulin therapy to minimize the risk of
hypoglycemia episodes, this does not always
occur in practice [30].
The limitations of the A1chieve study design
have been discussed previously [20] and include
the following: the lack of randomization, the
absence of a control arm, and the absence of
control for concomitant medication, dietary or
lifestyle changes. In addition, the reporting of
hypoglycemia events was based on patient
recall of events over the preceding 4 weeks;
although unlikely to affect the recording of
major hypoglycemia episodes, this may have
resulted in underestimation of mild events.
Another limitation was that dose titration to
optimize glycemic control was not a stipulation
of this observational study and, therefore,
glycemic control could have been better than
recorded. A further improvement in glycemic
control with up titration of insulin dose would
appear realistic given the low rate of
hypoglycemia events. Statistical power may
also be limited in this sub-analysis as it
includes a small proportion of the total
A1chieve cohort of patients. Despite these
limitations, the results from this analysis are
highly informative, given that they are derived
from a large number of patients, and also from a
wide geographical range, including many less
developed world economies, whose standards of
clinical practice with respect to type 2 diabetes
mellitus are less well documented.
The A1chieve study demonstrated that some
healthcare professionals prefer to start patients
on insulin therapy with prandial rather than
basal insulin [20], and add basal insulin when
required. Our sub-analysis shows that this
strategy can be effective and well tolerated for
the management of type 2 diabetes mellitus in
patients poorly controlled on other treatment
regimens. These findings warrant further
investigation in clinical trials, given recent
calls for an individualized approach to
initiation of insulin regimens in people with
type 2 diabetes mellitus and sub-optimal
glycemic control [31].
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